Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 10, Issue 2, 2010, Pages 153-162

  Labrada, Mayrel ^a   Clavell, Marilyn ^a   Bebelagua, Yanín ^a   De León, Joel ^a   Alonso, Daniel F ^b   Gabri, Mariano R ^b   Veloso, Roberto C ^c   Vérez, Vicente ^c   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c Center of Biomolecular Chemistry   (Cuba)

Author keywords

Cancer immunotherapy; Ganglioside; NGcGM3; VSSP

Indexed keywords

CANCER VACCINE; GANGLIOSIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14F7; NGCGM 3 GANGLIOSIDE; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; IMMUNOGENICITY; INNATE IMMUNITY; LEWIS CARCINOMA; LUNG METASTASIS; METASTASIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; G(M3) GANGLIOSIDE; HORSES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG; LUNG NEOPLASMS; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS;

ANIMALIA; GALLUS GALLUS; MURINAE; MUS; NEISSERIA MENINGITIDIS;

EID: 76149119805     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903443084     Document Type: Article

References (60)

1. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64(3):529-564
2. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10(3):281-287
3. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95(13):7556-7561
4. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92(25):11810-11813
5. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15(17):5323-5337
6. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009;9(9):675-681
7. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006;98(18):1292-1301
8. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6(3):204-216
9. Lage A, Perez R, Fernandez LE. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets 2005;5(8):611-627
10. Saito M, Kitamura H, Sugiyama K. Liver gangliosides of various animals ranging from fish to mammalian species. Comp Biochem Physiol B Biochem Mol Biol 2001;129(4):747-758
11. Saito M, Sugiyama K. Major and c-series gangliosides in lenticular tissues: mammals to molluscs. Comp Biochem Physiol B Biochem Mol Biol 2001;130(3):313-321
12. Suzaki K. The pattern of mammalian brain gangliosides. 3. Regional and developmental differences. J Neurochem 1965;12(12):969-979
13. Wang B, Miller JB, McNeil Y, McVeagh P. Sialic acid concentration of brain gangliosides: variation among eight mammalian species. Comp Biochem Physiol A Mol Integr Physiol 1998;119(1):435-439
14. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco)lipid metabolism. Cancer Res 1996;56(23):5309-5318
15. Livingston PO, Hood C, Krug LM, et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 2005;54(10):1018-1025
16. Livingston PO, Ragupathi G. Cancer vaccines targeting carbohydrate antigens. Hum Vaccin 2006;2(3):137-143
17. Portoukalian J, Zwingelstein G, Dore JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979;94(1):19-23
18. Birkle S, Zeng G, Gao L, et al. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003;85(3-4):455-463
19. Deng W, Li R, Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 2000;92(11):912-917
20. Alessandri G, Filippeschi S, Sinibaldi P, et al. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987;47(16):4243-4247
21. Ladisch S. Tumor cell gangliosides. Adv Pediatr 1987;34:45-58
22. Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987;79(6):1879-1882
23. Ladisch S, Wu ZL, Feig S, et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987;39(1):73-76
24. Varki A. Selectins and other mammalian sialic acid-binding lectins. Curr Opin Cell Biol 1992;4(2):257-266
25. Varki A. Diversity in the sialic acids. Glycobiology 1992;2(1):25-40
26. Muchmore EA, Milewski M, Varki A, Diaz S. Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. J Biol Chem 1989;264(34):20216-20223
27. Varki A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol 2001;(Suppl 33):54-69
28. Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie 2001;83(7):615-622
29. Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001;83(7):623-634
30. Marquina G, Waki H, Fernandez LE, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996;56(22):5165-5171
31. Oliva JP, Valdes Z, Casaco A, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc. Breast Cancer Res Treat 2006;96(2):115-121
32. Carr A, Mullet A, Mazorra Z, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19(3):241-247
33. de Leon J, Fernandez A, Mesa C, et al. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006;55(4):443-450
34. de Leon J, Fernandez A, Clavell M, et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4 +CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008;20(4):591-600
35. Carr A, Rodriguez E, Arango Mdel C, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003;21(6):1015-1021
36. Estevez F, Carr A, Solorzano L, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999;18(1-2):190-197
37. Eisenbach L, Hollander N, Greenfeld L, et al. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984;34(4):567-573
38. Muthing J, Steuer H, Peter-Katalinic J, et al. Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin. J Biochem 1994;116(1):64-73
39. Duclos RI Jr. The total synthesis of ganglioside GM3. Carbohydr Res 2000;328(4):489-507
40. Sherman AA, Yudina ON, Shashkov AS, et al. Preparative route to N-glycolylneuraminic acid phenyl 2-thioglycoside donor and synthesis of Neu5Gc-alpha-(2!3¢)-lactosamine 3-aminopropyl glycoside. Carbohydr Res 2002;337(5):451-457
41. Saito M, Kasai N, Yu RK. In situ immunological determination of basic carbohydrate structures of gangliosides on thin-layer plates. Anal Biochem 1985;148(1):54-58
42. Alonso DF, Gabri MR, Guthmann MD, et al. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol 1999;15(1):59-66
43. Coulombe J, Pelletier G. Gangliosides and organ-specific metastatic colonization. Int J Cancer 1993;53(1):104-109
44. Makatsori E, Fermani K, Aletras A, et al. Screening of N-acylneuraminic acids in serum and tissue specimens of mouse C57BI with Lewis' lung cancer by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998;712(1-2):23-29
45. El-Abbadi M, Seyfried TN, Yates AJ, et al. Ganglioside composition and histology of a spontaneous metastatic brain tumour in the VM mouse. Br J Cancer 2001;85(2):285-292
46. Dickler MN, Ragupathi G, Liu NX, et al. Immunogenicity of a fucosyl-GM1- keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 1999;5(10):2773-2779
47. Dumontet C, Rebbaa A, Portoukalian J. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice. J Immunol Methods 1997;206(1-2):115-123
48. Livingston PO, Calves MJ, Helling F, et al. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993;11(12):1199-1204
49. Livingston PO, Calves MJ, Natoli EJ Jr. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol 1987;138(5):1524-1529
50. Livingston PO, Ritter G, Calves MJ. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol Immunother 1989;29(3):179-184
51. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49(24 Pt 1):7045-7050
52. Zhang H, Zhang S, Cheung NK, et al. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998;58(13):2844-2849
53. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55(13):2783-2788
54. Kim SK, Ragupathi G, Cappello S, et al. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000;19(4-5):530-537
55. Livingston PO. Experimental and clinical studies with active specific immunotherapy. Prog Clin Biol Res 1989;288:309-321
56. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995;145:147-166
57. Livingston PO, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997;45(1):10-19
58. Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1995;6(6):357-366
59. Ravindranath MH, Kelley MC, Jones RC, et al. Ratio of IgG:IgM antibodies to sialyl LewisX and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer 1998;75(1):117-124
60. Ambrosino DM, Bolon D, Collard H, et al. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J Immunol 1992;149(12):3978-3983